HyperQure RDN System
HQ-HTN-G01 is a prospective, multicenter, single arm, open label, early feasibility study to evaluate initial safety and device design concept of "HyperQureTM RDN System", laparoscopic renal denervation therapy, in patients with resistant…
- Investigator
- Mark S Segal
- Status
- Accepting Candidates
- Ages
- 22 Years - 80 Years
- Sexes
- All
EASi-KIDNEY
- Investigator
- Mark S Segal
- Status
- Accepting Candidates
REGEN-006
The purpose of this study is to assess the safety and efficacy (including durability) of up to 2 REACT injections given 3 months (+30 days) apart and delivered percutaneously into biopsied and non-biopsied contralateral kidneys in participants with…
- Investigator
- Mark S Segal
- Status
- Accepting Candidates
- Ages
- 30 Years - 80 Years
- Sexes
- All
